AstraZeneca_NN
Annual_JJ
Report_NN
and_CC
Additional_JJ
Information_NOMZ
Form_NN
20-F_JJ
Information_NOMZ
2004_CD
for_PIN
US_FPP1
Investors_NN
125_CD
Additional_JJ
Information_NOMZ
for_PIN
US_FPP1
Investors_NN
Introduction_NOMZ
recorded_VBD
as_IN
goodwill_NN
._.
The_DT
amount_NN
allocated_VBN [WZPAST]
On_PIN
disposal_NN
of_PIN
a_DT
business_NOMZ
,_,
the_DT
gain_NN
or_CC
loss_NN
The_DT
accompanying_VBG
consolidated_JJ
Financial_NN
to_PIN
in-process_JJ
research_NN
and_PHC
development_NOMZ
under_IN
US_FPP1
GAAP_NN
may_POMD
differ_VB
from_PIN
that_DEMO
under_IN
Statements_NOMZ
included_VBD
in_PIN
this_DEMO
Annual_JJ
Report_NN
was_VBD
,_,
as_IN
required_VBN [SUAV]
by_PIN
US_FPP1
GAAP_NN
,_,
expensed_VBD
UK_NN
GAAP_NN
due_JJ
principally_RB
to_PIN
goodwill_NN
are_VPRT [PASS]
prepared_VBN
in_PIN
accordance_NN
with_PIN
UK_NN
GAAP_NN
._.
immediately_TIME
in_PIN
the_DT
first_JJ
reporting_GER
period_NN
after_IN
capitalized_JJ
and_PHC
amortised_JJ
,_,
together_RB
with_PIN
the_DT
There_EX
are_VPRT
certain_JJ
significant_JJ
differences_NN
the_DT
business_NOMZ
combination_NOMZ
._.
Fair_NN
value_NN
appropriate_JJ
share_NN
of_PIN
other_JJ
differences_NN
between_PIN
UK_NN
GAAP_NN
and_PHC
US_FPP1
GAAP_NN
which_WDT [WHOBJ]
adjustments_NOMZ
to_PIN
the_DT
recorded_VBN
amount_NN
of_PIN
between_PIN
UK_NN
and_PHC
US_FPP1
accounting_GER
principles_NN
affect_VPRT
AstraZenecas_NN
net_JJ
income_NN
and_PHC
inventory_NN
were_VBD [PASS]
expensed_VBN
in_PIN
the_DT
period_NN
recognized_VBN [PRIV] [WZPAST]
previously_TIME
._.
shareholders_NN
equity_NOMZ
and_CC
,_,
on_PIN
pages_NN
125_CD
to_PIN
the_DT
inventory_NN
was_VBD [PASS]
utilised_VBN
._.
Additional_JJ
135_CD
,_,
additional_JJ
information_NOMZ
under_IN
US_FPP1
GAAP_NN
amortisation_NOMZ
and_PHC
depreciation_NOMZ
have_VPRT
Capitalisation_NOMZ
of_PIN
interest_NN
is_VPRT [PASS]
set_VBN
out_PIN
as_IN
follows_VPRT
:_:
also_RB
been_VBN [PASS]
recorded_VBN
in_PIN
respect_NN
of_PIN
the_DT
fair_JJ
AstraZeneca_NN
does_VPRT
not_XX0
capitalize_VB
interest_NN
in_PIN
its_PIT
value_NN
adjustments_NOMZ
to_PIN
tangible_JJ
and_CC
UK_NN
GAAP_NN
Financial_NN
Statements_NOMZ
._.
US_FPP1
GAAP_NN
summary_NN
of_PIN
differences_NN
between_PIN
UK_NN
intangible_JJ
assets_NN
._.
requires_VPRT [SUAV] [THATD]
interest_NN
incurred_VBN
as_IN
part_NN
of_PIN
the_DT
cost_NN
and_PHC
US_FPP1
GAAP_NN
accounting_GER
principles_NN
:_:
of_PIN
constructing_VBG
fixed_JJ
assets_NN
to_TO
be_VB [PASS]
capitalized_VBN
page_NN
125_CD
In_PIN
the_DT
consolidated_JJ
Financial_NN
Statements_NOMZ
and_CC
amortised_VBN
over_IN
the_DT
life_NN
of_PIN
the_DT
asset_NN
._.
prepared_VBN
under_IN
UK_NN
GAAP_NN
,_,
goodwill_NN
arising_VBG [WZPRES]
net_JJ
income_NN
:_:
page_NN
128_CD
on_PIN
acquisitions_NOMZ
made_VBN [WZPAST]
prior_RB
to_PIN
1_CD
January_NN
1998_CD
Dividends_NN
accounted_VBD
for_PIN
under_IN
the_DT
purchase_NN
method_NN
Under_IN
UK_NN
GAAP_NN
,_,
Ordinary_NN
Share_NN
dividends_NN
US_FPP1
GAAP_NN
condensed_JJ
consolidated_JJ
has_VPRT [PEAS]
been_VBN [PASS]
eliminated_VBN
against_PIN
shareholders_NN
proposed_VBN [SUAV] [WZPAST]
are_VPRT [PASS]
provided_VBN
for_PIN
in_PIN
the_DT
year_NN
in_PIN
statement_NOMZ
of_PIN
operations_NOMZ
:_:
page_NN
129_CD
equity_NOMZ
._.
Under_IN
the_DT
requirements_NOMZ
of_PIN
UK_NN
respect_NN
of_PIN
which_WDT [PIRE]
they_TPP3
are_VPRT [BYPA]
recommended_VBN [SUAV]
by_PIN
Financial_NN
Reporting_GER
Standard_NN
10_CD
Goodwill_NN
the_DT
Board_NN
of_PIN
Directors_NN
for_PIN
approval_NN
by_PIN
the_DT
US_FPP1
GAAP_NN
statement_NOMZ
of_PIN
comprehensive_JJ
and_PHC
Intangible_JJ
Assets_NN
,_,
goodwill_NN
on_PIN
shareholders_NN
._.
Under_IN
US_FPP1
GAAP_NN
,_,
such_JJ
income_NN
:_:
page_NN
129_CD
acquisitions_NOMZ
made_VBN
after_IN
1_CD
January_NN
1998_CD
is_VPRT
dividends_NN
are_VPRT [PASS]
not_XX0
provided_VBN
for_PIN
until_IN
declared_VBN [PUBV]
capitalized_JJ
and_PHC
amortised_JJ
over_IN
its_PIT
estimated_VBN [PRIV]
by_PIN
the_DT
Board_NN
._.
stock-based_JJ
compensation_NOMZ
:_:
page_NN
130_CD
useful_JJ
life_NN
which_WDT [WHSUB]
is_VPRT [SPAU] [PASS]
generally_RB
presumed_VBN [PRIV]
not_XX0
to_TO
exceed_VB
20_CD
years_NN
._.
UK_NN
GAAP_NN
requires_VPRT [SUAV]
that_THVC
Deferred_JJ
taxation_NOMZ
pension_NN
and_PHC
post-retirement_NOMZ
benefits_NN
:_:
on_PIN
subsequent_JJ
disposal_NN
or_CC
termination_NOMZ
of_PIN
a_DT
Deferred_JJ
taxation_NOMZ
is_VPRT [PASS]
provided_VBN
on_PIN
a_DT
full_JJ
liability_NOMZ
page_NN
131_CD
previously_TIME
acquired_VBN
business_NOMZ
,_,
any_QUAN
goodwill_NN
basis_NN
under_IN
US_FPP1
GAAP_NN
,_,
which_WDT [SERE]
permits_VPRT
previously_TIME
taken_VBN
directly_RB
to_PIN
shareholders_NN
deferred_VBN
tax_NN
assets_NN
to_TO
be_VB [PASS]
recognized_VBN [PRIV]
if_COND
their_TPP3
taxation_NOMZ
:_:
page_NN
133_CD
equity_NOMZ
is_VPRT [SPAU] [PASS]
then_RB
charged_VBN
in_PIN
the_DT
income_NN
realisation_NOMZ
is_VPRT [PASS]
considered_VBN [PRIV]
to_TO
be_VB [BEMA]
more_EMPH
likely_JJ
statement_NOMZ
against_PIN
the_DT
profit_NN
or_CC
loss_NN
on_PIN
than_PIN
not_XX0
._.
Under_IN
current_JJ
UK_NN
GAAP_NN
,_,
full_JJ
shareholders_NN
equity_NOMZ
:_:
page_NN
134_CD
disposal_NN
or_CC
termination_NOMZ
._.
Up_IN
until_IN
1_CD
January_NN
provision_NN
is_VPRT [SPAU] [PASS]
also_RB
made_VBN
although_CONC
there_EX
are_VPRT
a_DT
2002_CD
,_,
under_IN
US_FPP1
GAAP_NN
,_,
goodwill_NN
was_VBD
number_NN
of_PIN
different_JJ
bases_NN
on_PIN
which_WDT [PIRE]
this_DEMP
acquired_VBN
intangible_JJ
assets_NN
and_PHC
goodwill_NN
:_:
required_VBN [SUAV]
to_TO
be_VB [PASS]
capitalized_VBN
and_PHC
amortised_VBN
._.
calculation_NOMZ
is_VPRT [PASS]
made_VBN
,_,
for_CONJ
example_NULL
rolled_VBD
over_IN
page_NN
134_CD
Now_TIME
,_,
instead_CONJ
of_NULL
being_VBG [WZPRES] [PASS]
amortised_VBN
,_,
goodwill_NN
capital_NN
gains_NN
._.
is_VPRT [PASS]
tested_VBN
annually_RB
for_PIN
impairment_NOMZ
._.
US_FPP1
GAAP_NN
condensed_JJ
consolidated_JJ
Pension_NN
and_PHC
post-retirement_NOMZ
benefits_NN
statement_NOMZ
of_PIN
cash_NN
flows_NN
:_:
page_NN
135_CD
Identifiable_JJ
intangible_JJ
assets_NN
,_,
which_WDT [SERE]
There_EX
are_VPRT
four_CD
main_JJ
differences_NN
between_PIN
principally_RB
include_VPRT
patents_NN
,_,
know-how_NN
current_JJ
UK_NN
GAAP_NN
and_PHC
US_FPP1
GAAP_NN
in_PIN
Differences_NN
between_PIN
UK_NN
and_PHC
US_FPP1
and_PHC
product_NN
registrations_NOMZ
,_,
are_VPRT [BEMA]
amortised_JJ
accounting_GER
for_PIN
pension_NN
costs_NN
:_:
accounting_GER
principles_NN
over_IN
their_TPP3
estimated_VBN [PRIV]
useful_JJ
lives_NN
which_WDT [WHSUB]
vary_VPRT
between_PIN
five_CD
years_NN
and_CC
20_CD
years_NN
with_PIN
a_DT
i_FPP1
US_FPP1
GAAP_NN
requires_VPRT [SUAV]
measurements_NOMZ
of_PIN
Purchase_NN
accounting_GER
adjustments_NOMZ
weighted_VBN
average_JJ
life_NN
of_PIN
approximately_RB
plan_NN
assets_NN
and_PHC
obligations_NOMZ
to_TO
be_VB [PASS]
made_VBN
Under_IN
UK_NN
GAAP_NN
,_,
the_DT
merger_NN
of_PIN
Astra_NN
and_CC
13_CD
years_NN
._.
as_RB
at_PIN
the_DT
date_NN
of_PIN
the_DT
financial_JJ
statements_NOMZ
Zeneca_NN
was_VBD [PASS]
accounted_VBN
for_PIN
as_IN
a_DT
merger_NN
of_PIN
or_CC
a_DT
date_NN
not_XX0
more_EMPH
than_PIN
three_CD
months_NN
equals_VPRT
pooling-of-interests_NN
._.
Under_IN
US_FPP1
At_PIN
31_CD
December_NN
2004_CD
and_CC
2003_CD
under_IN
US_FPP1
prior_RB
to_PIN
that_DEMO
date_NN
._.
Under_IN
UK_NN
GAAP_NN
,_,
GAAP_NN
the_DT
merger_NN
was_VBD [PASS]
accounted_VBN
for_PIN
as_IN
the_DT
GAAP_NN
,_,
shareholders_NN
equity_NOMZ
includes_VPRT
calculations_NOMZ
may_POMD
be_VB [PASS]
based_VBN
on_PIN
the_DT
results_NN
acquisition_NOMZ
of_PIN
Astra_NN
by_PIN
Zeneca_NN
using_VBG [WZPRES]
capitalized_JJ
goodwill_NN
of_PIN
$_$
16,143_CD
m_NN
and_CC
of_PIN
the_DT
latest_JJ
actuarial_JJ
valuation_NOMZ
:_:
purchase_NN
accounting_GER
._.
Under_IN
purchase_NN
$_$
15,306_CD
m_NN [BEMA]
respectively_RB
net_PRED
of_PIN
amortisation_NOMZ
accounting_GER
,_,
the_DT
cost_NN
of_PIN
the_DT
investment_NOMZ
is_VPRT
and_CC
impairment_NOMZ
of_PIN
$_$
2,698_CD
m_NN
and_CC
$_$
2,596_CD
m_NN
ii_FW
US_FPP1
GAAP_NN
mandates_VPRT
a_DT
particular_JJ
calculated_VBN [PRIV]
at_PIN
the_DT
market_NN
value_NN
of_PIN
the_DT
shares_NN
and_CC
capitalized_JJ
identifiable_JJ
intangible_JJ
assets_NN
actuarial_JJ
method_NN
the_DT
projected_VBN
unit_NN
issued_VBN [WZPAST]
together_RB
with_PIN
other_JJ
incidental_JJ
costs_NN
of_PIN
$_$
8,854_CD
m_NN
and_CC
$_$
9,536_CD
m_NN [BEMA]
respectively_RB
net_JJ
credit_NN
method_NN
and_CC
requires_VPRT [SUAV]
that_THVC
each_QUAN
and_CC
the_DT
assets_NN
and_PHC
liabilities_NOMZ
of_PIN
the_DT
acquired_VBN
of_PIN
amortisation_NOMZ
and_PHC
impairment_NOMZ
of_PIN
$_$
8,514_CD
m_NN [BEMA]
significant_JJ
assumption_NOMZ
necessary_JJ
to_PIN
entity_NOMZ
are_VPRT [PASS]
recorded_VBN
at_PIN
fair_JJ
value_NN
._.
Goodwill_NN
on_PIN
businesses_NOMZ
determine_VPRT [SUAV] [PRIV]
annual_JJ
pension_NN
costs_NN
reflects_VPRT [PRIV]
the_DT
fair_JJ
value_NN
exercise_NN
,_,
increases_NN
in_PIN
the_DT
values_NN
disposed_VBD
of_PIN
is_VPRT [PASS]
charged_VBN
to_PIN
the_DT
gain_NN
or_CC
loss_NN
best_JJ
estimates_NN
solely_RB
with_PIN
regard_NN
to_PIN
that_DEMO
of_PIN
Astras_NN
tangible_JJ
fixed_VBN
assets_NN
and_PHC
inventory_NN
on_PIN
disposal_NN
._.
UK_NN
GAAP_NN
does_EMPH
were_VBD [PASS]
recognized_VBN [PRIV]
and_PHC
values_VPRT
attributed_VBN
to_PIN
its_PIT
not_XX0
mandate_VB
a_DT
particular_JJ
method_NN
,_,
but_CC
in-process_JJ
research_NN
and_PHC
development_NOMZ
and_CC
requires_VPRT [SUAV]
that_THVC
the_DT
method_NN
and_CC
existing_VBG
products_NN
,_,
together_RB
with_PIN
appropriate_JJ
assumptions_NOMZ
taken_VBN
as_IN
a_DT
whole_JJ
should_NEMD
be_VB [PASS]
deferred_VBN
taxation_NOMZ
effects_NN
._.
The_DT
difference_NN
compatible_JJ
and_PHC
lead_JJ
to_PIN
the_DT
actuarys_NN
best_JJ
between_PIN
the_DT
cost_NN
of_PIN
investment_NOMZ
and_CC
the_DT
fair_JJ
estimate_NN
of_PIN
the_DT
cost_NN
of_PIN
providing_VBG
the_DT
value_NN
of_PIN
the_DT
assets_NN
and_PHC
liabilities_NOMZ
of_PIN
Astra_NN
was_VBD [PASS]
benefits_NN
promised_VBN [PUBV]
:_:
AstraZeneca_NN
Annual_JJ
Report_NN
and_CC
Additional_JJ
Information_NOMZ
126_CD
Form_NN
20-F_JJ
Information_NOMZ
2004_CD
for_PIN
US_FPP1
Investors_NN
Additional_JJ
Information_NOMZ
for_PIN
US_FPP1
Investors_NN
continued_VBD
Differences_NN
between_PIN
UK_NN
and_PHC
US_FPP1
such_JJ
deferral_NN
is_VPRT [PASS]
not_XX0
permitted_VBN
except_PIN
in_PIN
between_PIN
the_DT
standards_NN
relate_VPRT
to_TO
accounting_VBG
principles_NN
continued_VBD
certain_JJ
defined_VBN
circumstances_NN
._.
Under_IN
FRS_NN
1_CD
,_,
the_DT
Company_NN
presents_VPRT
its_PIT
cash_NN
flows_VPRT
for_PIN
a_DT
operating_GER
iii_NN
under_IN
US_FPP1
GAAP_NN
,_,
a_DT
negative_JJ
pension_NN
cost_NN
Financial_NN
instruments_NOMZ
and_CC
hedging_VBG
activities_NOMZ
:_:
b_NN
dividends_NN
received_VBN [WZPAST]
from_PIN
joint_NN
may_POMD
arise_VB
where_RB
a_DT
significant_JJ
activities_NOMZ
ventures_NN
and_PHC
associates_NN
:_:
c_NN
returns_NN
on_PIN
unrecognised_JJ
net_JJ
asset_NN
or_CC
gain_NN
exists_VPRT
at_PIN
Under_IN
US_FPP1
GAAP_NN
,_,
all_QUAN
derivative_JJ
instruments_NOMZ
investments_NOMZ
and_PHC
servicing_GER
of_PIN
finance_NN
:_:
the_DT
time_NN
of_PIN
implementation_NOMZ
._.
This_DEMP
is_VPRT
should_NEMD
be_VB [PASS]
recognized_VBN [PRIV]
as_IN
assets_NN
or_CC
liabilities_NOMZ
in_PIN
d_SYM
tax_NN
paid_VBN
:_:
e_LS
capital_NN
expenditure_NN
and_CC
required_VBN [SUAV]
to_TO
be_VB [PASS]
amortised_VBN
on_PIN
a_DT
straightthe_JJ
balance_NN
sheet_NN
at_PIN
fair_JJ
value_NN
._.
Gains_NN
and_CC
financial_JJ
investment_NOMZ
:_:
f_LS
acquisitions_NOMZ
and_PHC
line_NN
basis_NN
over_IN
the_DT
average_JJ
remaining_JJ
losses_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
net_JJ
income_NN
unless_COND
disposals_NN
:_:
g_VB
dividends_NN
paid_VBN [WZPAST]
to_PIN
shareholders_NN
:_:
service_NN
period_NN
of_PIN
employees_NN
._.
Under_IN
UK_NN
they_TPP3
are_VPRT [PASS]
regarded_VBN
as_IN
hedges_NN
._.
Under_IN
UK_NN
h_VPRT
management_NOMZ
of_PIN
liquid_JJ
resources_NN
:_:
and_ANDC
GAAP_NN
,_,
AstraZenecas_NN
policy_NN
is_VPRT [BEMA]
not_XX0
to_PIN
GAAP_NN
,_,
these_DEMO
instruments_NOMZ
are_VPRT [PASS]
measured_VBN
at_PIN
i_FPP1
financing_GER
._.
95_CD
requires_VPRT [SUAV]
only_DWNT
three_CD
recognize_VPRT [PRIV]
pension_NN
credits_NN
in_PIN
its_PIT
Financial_NN
cost_NN
and_PHC
gains_NN
or_CC
losses_NN
deferred_VBN
until_IN
the_DT
categories_NN
of_PIN
cash_NN
flow_NN
activity_NOMZ
being_VBG [WZPRES]
Statements_NOMZ
unless_COND
a_DT
refund_NN
of_PIN [STPR]
,_,
or_CC
underlying_VBG
transactions_NOMZ
occur_VPRT
._.
reduction_NOMZ
in_PIN [STPR]
,_,
contributions_NOMZ
is_VPRT [BEMA]
likely_PRED
:_:
and_ANDC
Under_IN
US_FPP1
GAAP_NN
,_,
marketable_JJ
securities_NOMZ
are_VPRT
Cash_NN
flows_VPRT
from_PIN
taxation_NOMZ
,_,
returns_NN
on_PIN
iv_NN
under_IN
US_FPP1
GAAP_NN
,_,
a_DT
minimum_JJ
pension_NN
recognized_VBN [PRIV] [WZPAST]
at_PIN
fair_JJ
value_NN
,_,
with_PIN
movements_NOMZ
in_PIN
investments_NOMZ
and_PHC
servicing_GER
of_PIN
finance_NN
and_PHC
liability_NOMZ
is_VPRT [PASS]
recognized_VBN [PRIV]
through_PIN
other_JJ
fair_JJ
value_NN
taken_VBN [WZPAST]
to_PIN
a_DT
separate_JJ
component_NN
of_PIN
dividends_NN
received_VBN [WZPAST]
from_PIN
joint_JJ
ventures_NN
and_CC
comprehensive_JJ
income_NN
in_PIN
certain_JJ
equity_NOMZ
._.
Under_IN
UK_NN
GAAP_NN
,_,
such_JJ
investments_NOMZ
associates_NN
under_IN
FRS_NN
1_CD
would_PRMD
be_VB [PASS]
included_VBN
circumstances_NN
when_RB
there_EX
is_VPRT
a_DT
deficit_NN
of_PIN
are_VPRT [PASS]
held_VBN [PRIV]
at_PIN
cost_NN
._.
as_IN
operating_VBG
activities_NOMZ
under_IN
SFAS_NN
No._NN
._.
95_CD
:_:
plan_NN
assets_NN
relative_JJ
to_PIN
the_DT
accumulated_VBN
capital_NN
expenditure_NN
and_CC
financial_JJ
investment_NOMZ
benefits_NN
obligation_NOMZ
._.
Under_IN
UK_NN
GAAP_NN
,_,
Deferred_JJ
income_NN
and_PHC
acquisitions_NOMZ
and_PHC
disposals_NN
would_PRMD
be_VB
there_EX
is_VPRT
no_SYNE
such_JJ
requirement_NOMZ
._.
Under_IN
UK_NN
GAAP_NN
,_,
profits_NN
or_CC
losses_NN
from_PIN
the_DT
included_VBN
as_IN
investing_VBG
activities_NOMZ
:_:
and_ANDC
sale_NN
of_PIN
product_NN
related_VBN
intangible_JJ
assets_NN
are_VPRT
distributions_NOMZ
would_PRMD
be_VB [PASS]
included_VBN
as_IN
a_DT
Restructuring_GER
costs_NN
generally_RB
taken_VBN
to_PIN
other_JJ
operating_GER
income_NN
at_PIN
financing_GER
activity_NOMZ
under_IN
SFAS_NN
No._NN
._.
Under_IN
Under_IN
UK_NN
GAAP_NN
,_,
provisions_NN
are_VPRT [PASS]
made_VBN
for_PIN
disposal_NN
and_CC
are_VPRT [PASS]
stated_VBN [PUBV]
after_IN
taking_VBG
account_NN
FRS_NN
1_CD
cash_NN
comprises_VPRT
cash_NN
in_PIN
hand_NN
and_PHC
restructuring_GER
costs_NN
once_TIME
a_DT
detailed_JJ
formal_JJ
of_PIN
product_NN
disposal_NN
costs_NN
and_PHC
costs_NN
of_PIN
minor_JJ
deposits_NN
repayable_JJ
on_PIN
demand_NN
,_,
less_JJ
plan_NN
is_VPRT [BEMA]
in_PIN
place_NN
and_CC
valid_JJ
expectations_NOMZ
have_VPRT
outstanding_JJ
obligations_NOMZ
._.
Under_IN
US_FPP1
GAAP_NN
,_,
overdrafts_VPRT
repayable_JJ
on_PIN
demand_NN
:_:
and_ANDC
liquid_JJ
been_VBN [PASS]
raised_VBN
in_PIN
those_DEMP
affected_VBN
that_DEMO
the_DT
such_JJ
profits_NN
are_VPRT [PASS]
deferred_VBN
and_PHC
recognized_VBN [PRIV]
in_PIN
resources_NN
comprise_VPRT
current_JJ
asset_NN
restructuring_GER
will_PRMD
be_VB [PASS]
carried_VBN
out_PIN [STPR]
._.
US_FPP1
GAAP_NN
the_DT
income_NN
statement_NOMZ
in_PIN
subsequent_JJ
periods_NN
investments_NOMZ
held_VBD [PRIV]
as_IN
readily_RB
disposable_JJ
stores_NN
requires_VPRT [SUAV]
a_DT
number_NN
of_PIN
specific_JJ
criteria_NN
to_TO
be_VB
until_IN
all_QUAN
disposal_NN
obligations_NOMZ
and_CC
of_PIN
value_NN
._.
95_CD
cash_NN
met_VBD
before_IN
such_JJ
costs_NN
can_POMD
be_VB [PASS]
recognized_VBN [PRIV]
as_IN
commitments_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
completed_VBN
._.
equivalents_NN
,_,
comprising_VBG
short_JJ
term_NN
highly_AMP
an_DT
expense_NN
._.
Among_PIN
these_DEMP
are_VPRT [BEMA]
the_DT
liquid_JJ
investments_NOMZ
,_,
generally_RB
with_PIN
original_JJ
requirements_NOMZ
that_TOBJ
costs_NN
associated_VBN [WZPAST]
with_PIN
exit_NN
Stock-based_JJ
compensation_NOMZ
maturities_NOMZ
of_PIN
three_CD
months_NN
or_CC
less_JJ
,_,
are_VPRT
or_CC
disposal_NN
activities_NOMZ
are_VPRT [PASS]
recognized_VBN [PRIV]
when_RB [WHCL]
In_PIN
the_DT
Groups_NN
Financial_NN
Statements_NOMZ
prepared_VBD
grouped_VBN
together_RB
with_PIN
cash_NN
:_:
short_JJ
term_NN
the_DT
costs_NN
are_VPRT [PASS]
incurred_VBN
rather_RB
than_PIN
at_PIN
the_DT
date_NN
under_IN
UK_NN
GAAP_NN
,_,
no_SYNE
cost_NN
is_VPRT [PASS]
accrued_VBN
for_PIN
the_DT
borrowings_GER
repayable_JJ
on_PIN
demand_NN
would_PRMD
not_XX0
of_PIN
commitment_NOMZ
to_PIN
an_DT
exit_NN
or_CC
disposal_NN
plan_NN
._.
To_TO
share_VB
options_NOMZ
awarded_VBN [WZPAST]
to_PIN
employees_NN
under_IN
be_VB [PASS]
included_VBN
within_PIN
cash_NN
and_PHC
cash_NN
equivalents_NN
the_DT
extent_NN
that_TSUB
restructuring_VBG
costs_NN
are_VPRT [PASS]
related_VBN
the_DT
AstraZeneca_NN
Share_NN
Option_NOMZ
Plan_NN
and_CC
the_DT
and_CC
movements_NOMZ
on_PIN
those_DEMO
borrowings_GER
would_PRMD
to_PIN
the_DT
activities_NOMZ
of_PIN
the_DT
acquired_VBN
company_NN
,_,
US_FPP1
AstraZeneca_NN
Savings-Related_NN
Share_NN
Option_NOMZ
be_VB [PASS]
included_VBN
in_PIN
financing_GER
activities_NOMZ
._.
GAAP_NN
allows_VPRT [SUAV]
them_TPP3
to_TO
be_VB [PASS]
recognized_VBN [PRIV]
as_IN
a_DT
Plan_NN
as_IN
the_DT
exercise_NN
price_NN
is_VPRT [BEMA]
equivalent_PRED
to_PIN
the_DT
liability_NOMZ
upon_PIN
acquisition_NOMZ
._.
market_NN
value_NN
at_PIN
the_DT
date_NN
of_PIN
grant_NN
._.
Under_IN
US_FPP1
New_NN
accounting_GER
standards_NN
GAAP_NN
,_,
the_DT
cost_NN
is_VPRT [PASS]
calculated_VBN [PRIV]
as_IN
the_DT
difference_NN
FIN_NN
No._NN
._.
46R_CD
Consolidation_NOMZ
of_PIN
Variable_NN
Intangible_NN
assets_NN
between_PIN
the_DT
option_NOMZ
price_NN
and_CC
the_DT
market_NN
Interest_NN
Entities_NOMZ
VIE_NN
is_VPRT [PASS]
intended_VBN [SUAV]
to_TO
address_VB
Under_IN
UK_NN
GAAP_NN
,_,
AstraZeneca_NN
capitalises_VPRT
price_NN
at_PIN
the_DT
date_NN
of_PIN
grant_NN
or_CC
,_,
for_PIN
variable_JJ
perceived_VBN [PRIV]
weaknesses_NOMZ
in_PIN
accounting_GER
for_PIN
certain_JJ
defined_VBN
software_NN
costs_NN
and_PHC
amortises_NN
plans_NN
,_,
at_PIN
the_DT
end_NN
of_PIN
the_DT
reporting_GER
period_NN
until_IN
special_JJ
purpose_NN
or_CC
off-balance_JJ
sheet_NN
entities_NOMZ
these_DEMO
over_IN
five_CD
years_NN
._.
Under_IN
US_FPP1
GAAP_NN
,_,
measurement_NOMZ
date_NN
._.
Under_IN
the_DT
requirements_NOMZ
and_CC
provides_VPRT
guidance_NN
on_PIN
identifying_VBG
the_DT
software_NN
costs_NN
are_VPRT [SPAU] [PASS]
generally_RB
capitalized_VBN
and_CC
of_PIN
APB_NN
Opinion_NN
No._NN
._.
25_CD
any_QUAN
compensation_NOMZ
primary_JJ
beneficiary_NN
resulting_VBG [WZPRES]
from_PIN
amortised_VBN
over_IN
three_CD
to_PIN
five_CD
years_NN
._.
cost_NN
would_PRMD
be_VB [PASS]
charged_VBN
over_IN
the_DT
period_NN
from_PIN
arrangements_NOMZ
or_CC
financial_JJ
interests_NN
as_IN
the_DT
date_NN
the_DT
options_NOMZ
are_VPRT [PASS]
granted_VBN [SUAV]
to_PIN
the_DT
date_NN
opposed_VBN
to_TO
voting_VBG [SUAV]
rights_NN
._.
If_COND
a_DT
party_NN
is_VPRT [BEMA]
a_DT
Under_IN
UK_NN
GAAP_NN
certain_JJ
payments_NOMZ
for_PIN
rights_NN
they_TPP3
are_VPRT [BEMA]
first_JJ
exercisable_JJ
._.
Under_IN
US_FPP1
GAAP_NN
,_,
in_PIN
primary_JJ
beneficiary_NN
then_RB
the_DT
assets_NN
,_,
liabilities_NOMZ
to_PIN
compounds_NN
in_PIN
development_NOMZ
are_VPRT [BEMA]
the_DT
net_JJ
income_NN
reconciliation_NOMZ
,_,
the_DT
Group_NN
has_VPRT
and_PHC
results_VPRT
of_PIN
the_DT
VIE_NN
should_NEMD
be_VB [PASS]
included_VBN
in_PIN
capitalized_JJ
._.
Under_IN
US_FPP1
GAAP_NN
these_DEMP
adjusted_VBN
for_PIN
stock-based_JJ
compensation_NOMZ
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
of_PIN
the_DT
payments_NOMZ
are_VPRT [PASS]
expensed_VBN
._.
costs_NN
calculated_VBN [PRIV]
under_IN
APB_NN
Opinion_NN
No._NN
._.
46R_CD
applied_VBN
to_PIN
all_QUAN
VIEs_NN
or_CC
potential_JJ
VIEs_NN
referred_VBD
to_PIN
as_IN
special_JJ
purpose_NN
Foreign_JJ
exchange_NN
Statement_NOMZ
of_PIN
cash_NN
flows_NN
:_:
Basis_NN
of_PIN
entities_NOMZ
for_PIN
periods_NN
ending_VBG [WZPRES]
on_PIN
or_CC
after_IN
15_CD
Under_IN
UK_NN
GAAP_NN
,_,
unrealised_JJ
gains_NN
and_PHC
losses_NN
preparation_NOMZ
December_NN
2003_CD
._.
Adoption_NOMZ
for_PIN
all_QUAN
other_JJ
on_PIN
foreign_JJ
currency_NN
transactions_NOMZ
to_TO
hedge_VB
AstraZenecas_NN
statement_NOMZ
of_PIN
Group_NN
cash_NN
flow_NN
entities_NOMZ
was_VBD [PASS]
required_VBN [SUAV]
for_PIN
periods_NN
ending_VBG [WZPRES]
on_PIN
or_CC
anticipated_VBN [PRIV]
,_,
but_CC
not_XX0
firmly_RB
committed_VBN
,_,
foreign_JJ
is_VPRT [PASS]
prepared_VBN
in_PIN
accordance_NN
with_PIN
UK_NN
Financial_NN
after_IN
15_CD
March_NN
2004_CD
._.
46R_CD
did_VBD
not_XX0
currency_NN
transactions_NOMZ
may_POMD
be_VB [PASS]
deferred_VBN
and_CC
Reporting_GER
Standard_NN
1_CD
Revised_VBN
1996_CD
FRS_NN
have_VPRT
a_DT
material_NN
effect_NN
on_PIN
the_DT
results_NN
or_CC
net_JJ
accounted_VBD
for_PIN
at_PIN
the_DT
same_JJ
time_NN
as_IN
the_DT
1_CD
,_,
whose_WPS
objective_NN
and_PHC
principles_NN
are_VPRT [BEMA]
similar_JJ
assets_NN
of_PIN
AstraZeneca_NN
._.
Under_IN
US_FPP1
GAAP_NN
,_,
to_PIN
those_DEMP
set_VBN
out_PIN
in_PIN
SFAS_NN
No._NN
._.
The_DT
principal_JJ
differences_NN
AstraZeneca_NN
Annual_JJ
Report_NN
and_CC
Additional_JJ
Information_NOMZ
Form_NN
20-F_JJ
Information_NOMZ
2004_CD
for_PIN
US_FPP1
Investors_NN
127_CD
In_PIN
March_NN
2004_CD
,_,
the_DT
Emerging_VBG
Issues_NN
Task_NN
In_PIN
December_NN
2004_CD
,_,
the_DT
FASB_NN
issued_VBD
SFAS_NN
Force_NN
EITF_NN
issued_VBD
EITF_NN
Issue_NN
No._NN
._.
152_CD
Accounting_GER
for_PIN
Real_NN
Estate_NN
TimeParticipating_GER
Securities_NOMZ
and_CC
the_DT
Two-Class_NN
sharing_GER
Transactions_NOMZ
,_,
an_DT
amendment_NOMZ
of_PIN
Method_NN
under_IN
FASB_NN
Statement_NOMZ
No._NN
._.
66_CD
and_CC
67_CD
which_WDT
Earnings_GER
per_PIN
Share_NN
._.
This_DEMO
guidance_NN
provides_VPRT
that_DEMO
real_JJ
estate_NN
time-sharing_JJ
addressed_VBD
changes_NN
in_PIN
the_DT
reporting_GER
and_PHC
transactions_NOMZ
should_NEMD
be_VB [PASS]
accounted_VBN
for_PIN
as_IN
calculation_NOMZ
requirements_NOMZ
for_PIN
earnings_GER
per_PIN
non-retail_JJ
land_NN
sales_NN
._.
152_CD
is_VPRT
share_NN
,_,
setting_VBG [PRESP]
out_PIN
the_DT
method_NN
to_TO
be_VB [PASS]
used_VBN
effective_JJ
for_PIN
fiscal_JJ
years_NN
beginning_VBG [WZPRES]
after_IN
when_RB
a_DT
company_NN
has_VPRT [PEAS]
granted_VBN [SUAV]
holders_NN
of_PIN
any_QUAN
15_CD
June_NN
2005_CD
._.
The_DT
adoption_NOMZ
of_PIN
SFAS_NN
form_NN
of_PIN
security_NOMZ
rights_NN
to_TO
participate_VB
in_PIN
the_DT
No._NN
._.
152_CD
is_VPRT [PASS]
not_XX0
expected_VBN [PRIV]
to_TO
have_VB
a_DT
material_NN
earnings_GER
of_PIN
the_DT
company_NN
along_IN
with_PIN
the_DT
effect_NN
on_PIN
the_DT
net_JJ
assets_NN
or_CC
results_NN
of_PIN
participation_NOMZ
rights_NN
of_PIN
common_JJ
stockholders_NN
._.
The_DT
adoption_NOMZ
of_PIN
EITF_NN
03-6_CD
had_VBD
no_SYNE
effect_NN
on_PIN
AstraZeneca_NN
._.
In_PIN
December_NN
2004_CD
,_,
the_DT
FASB_NN
issued_VBD
SFAS_NN
No._NN
._.
153_CD
Exchanges_NN
of_PIN
Non-monetary_JJ
In_PIN
June_NN
2004_CD
,_,
the_DT
EITF_NN
issued_VBD
EITF_NN
Issue_NN
No._NN
._.
Assets_NN
,_,
an_DT
amendment_NOMZ
of_PIN
APB_NN
Opinion_NN
No._NN
._.
03-1_CD
The_DT
Meaning_GER
of_PIN
Other_JJ
Than_PIN
Temporary_JJ
29_CD
which_WDT
replaces_VPRT
the_DT
current_JJ
exception_NOMZ
Impairment_NOMZ
and_CC
Its_PIT
Application_NOMZ
to_PIN
Certain_NN
from_PIN
fair_JJ
value_NN
measurement_NOMZ
for_PIN
nonInvestments_NOMZ
._.
The_DT
guidance_NN
details_NN
how_RB
to_PIN
monetary_JJ
exchanges_NN
of_PIN
similar_JJ
productive_JJ
determine_VB [SUAV] [PRIV]
the_DT
meaning_GER
of_PIN
other_JJ
than_PIN
assets_NN
with_PIN
a_DT
general_JJ
exception_NOMZ
from_PIN
fair_JJ
temporary_JJ
impairment_NOMZ
and_CC
its_PIT
application_NOMZ
to_PIN
value_NN
measurement_NOMZ
for_PIN
exchanges_NN
of_PIN
nondebt_NN
and_PHC
equity_NOMZ
securities_NOMZ
within_PIN
the_DT
scope_NN
of_PIN
monetary_JJ
assets_NN
that_TSUB
do_VPRT
not_XX0
have_VB
SFAS_NN
No._NN
._.
115_CD
Accounting_GER
for_PIN
Certain_NN
commercial_JJ
substance_NN
._.
153_CD
shall_PRMD
Investments_NOMZ
in_PIN
Debt_NN
and_PHC
Equity_NOMZ
Securities_NOMZ
be_VB [PASS]
applied_VBN
prospectively_RB
and_CC
is_VPRT [BEMA]
effective_PRED
for_PIN
SFAS_NN
No._NN
._.
115_CD
and_CC
to_PIN
equity_NOMZ
securities_NOMZ
that_TOBJ
non-monetary_JJ
asset_NN
exchanges_NN
occurring_VBG [WZPRES]
in_PIN
are_VPRT [BEMA]
not_XX0
subject_PRED
to_PIN
the_DT
scope_NN
of_PIN
SFAS_NN
No._NN
._.
fiscal_JJ
periods_NN
beginning_VBG [WZPRES]
after_IN
15_CD
June_NN
2005_CD
._.
115_CD
and_CC
are_VPRT [PASS]
not_XX0
accounted_VBN
for_PIN
under_IN
the_DT
The_DT
adoption_NOMZ
of_PIN
SFAS_NN
No._NN
._.
153_CD
is_VPRT
not_XX0
equity_NOMZ
method_NN
of_PIN
accounting_GER
._.
The_DT
guidance_NN
expected_VBN [PRIV]
to_TO
have_VB
a_DT
material_NN
effect_NN
on_PIN
the_DT
also_RB
includes_VPRT
accounting_GER
considerations_NOMZ
results_NN
or_CC
net_JJ
assets_NN
of_PIN
AstraZeneca_NN
._.
subsequent_JJ
to_PIN
the_DT
recognition_NOMZ
of_PIN
an_DT
impairment_NOMZ
other_JJ
than_PIN
temporary_JJ
and_CC
In_PIN
December_NN
2004_CD
,_,
the_DT
FASB_NN
issued_VBD
SFAS_NN
requires_VPRT [SUAV]
certain_JJ
disclosures_NN
about_IN
unrealised_JJ
No._NN
._.
123_CD
R_NN
Share-Based_NN
Payment_NOMZ
that_TSUB
will_PRMD
losses_NN
that_TSUB
have_VPRT [PEAS]
not_XX0
been_VBN [PASS]
recognized_VBN [PRIV]
as_IN
require_VPRT [SUAV]
compensation_NOMZ
costs_NN
related_VBN [WZPAST]
to_PIN
shareother_JJ
than_PIN
temporary_JJ
impairments_NOMZ
._.
These_DEMP
based_VBN
payment_NOMZ
transactions_NOMZ
to_TO
be_VB
disclosure_NN
requirements_NOMZ
became_VBD
effective_JJ
for_PIN
recognized_VBN [PRIV]
in_PIN
the_DT
financial_JJ
statements_NOMZ
._.
With_PIN
periods_NN
ended_VBD
prior_RB
to_PIN
30_CD
June_NN
2004_CD
._.
The_DT
limited_JJ
exceptions_NOMZ
,_,
the_DT
amount_NN
of_PIN
introduction_NOMZ
of_PIN
recognition_NOMZ
and_PHC
compensation_NOMZ
cost_NN
will_PRMD
be_VB [PASS]
measured_VBN
based_VBN
measurement_NOMZ
guidance_NN
of_PIN
EITF_NN
03-1_CD
has_VPRT
on_PIN
the_DT
grant-date_JJ
fair_JJ
value_NN
of_PIN
the_DT
equity_NOMZ
or_CC
been_VBN [PASS]
deferred_VBN
._.
The_DT
disclosure_NN
requirements_NOMZ
liability_NOMZ
instruments_NOMZ
issued_VBN
._.
In_CONJ
addition_NULL
,_,
liability_NOMZ
did_VBD
not_XX0
have_VB
a_DT
significant_JJ
effect_NN
on_PIN
awards_NN
will_PRMD
be_VB [PASS]
remeasured_VBN
each_QUAN
reporting_GER
AstraZeneca_NN
:_:
it_PIT
is_VPRT [PASS]
not_XX0
expected_VBN [PRIV]
that_THVC
the_DT
period_NN
._.
Compensation_NOMZ
cost_NN
will_PRMD
be_VB
recognition_NOMZ
and_PHC
measurement_NOMZ
requirements_NOMZ
recognized_VBN [PRIV]
over_IN
the_DT
period_NN
that_TOBJ
an_DT
employee_NN
will_PRMD
have_VB
a_DT
material_NN
impact_NN
either_RB
._.
provides_VPRT
service_NN
in_PIN
exchange_NN
for_PIN
the_DT
award_NN
._.
123_CD
,_,
In_PIN
November_NN
2004_CD
,_,
the_DT
FASB_NN
issued_VBD
SFAS_NN
Accounting_GER
for_PIN
Stock-Based_NN
No._NN
._.
151_CD
Inventory_NN
Costs_NN
to_TO
clarify_VB
the_DT
Compensation_NOMZ
,_,
and_ANDC
supersedes_VPRT
APB_NN
accounting_GER
for_PIN
abnormal_JJ
amounts_NN
of_PIN
idle_JJ
Opinion_NN
No._NN
._.
25_CD
,_,
Accounting_GER
for_PIN
Stock_NN
facility_NOMZ
expense_NN
,_,
freight_NN
,_,
handling_VBG
costs_NN
,_,
and_ANDC
Issued_VBN
to_PIN
Employees_NN
._.
The_DT
effective_JJ
date_NN
wasted_VBN
material_NN
spoilage_NN
._.
123_CD
R_NN
is_VPRT
accounting_VBG
periods_NN
effective_JJ
for_PIN
inventory_NN
costs_NN
incurred_VBN [WZPAST]
during_PIN
commencing_VBG
on_PIN
or_CC
after_IN
15_CD
June_NN
2005_CD
._.
fiscal_JJ
years_NN
beginning_VBG [WZPRES]
after_IN
15_CD
June_NN
2005_CD
._.
The_DT
standard_NN
should_NEMD
be_VB [PASS]
applied_VBN
using_VBG
the_DT
The_DT
adoption_NOMZ
of_PIN
SFAS_NN
No._NN
._.
151_CD
is_VPRT [PASS]
not_XX0
modified_VBN
prospective_JJ
method_NN
although_CONC
there_EX
expected_VBN [PRIV]
to_TO
have_VB
a_DT
material_NN
effect_NN
on_PIN
the_DT
are_VPRT [BEMA]
transitional_JJ
arrangements_NOMZ
for_PIN
modified_VBN
results_NN
or_CC
net_JJ
assets_NN
of_PIN
AstraZeneca_NN
._.
retrospective_JJ
application_NOMZ
if_COND
the_DT
disclosure_NN
or_CC
recognition_NOMZ
requirements_NOMZ
of_PIN
SFAS_NN
No._NN
._.
AstraZeneca_NN
has_VPRT [PEAS]
not_XX0
yet_RB
determined_VBN [SUAV] [PRIV]
the_DT
effect_NN
of_PIN
the_DT
adoption_NOMZ
of_PIN
SFAS_NN
No._NN
._.
123_CD
R._NN
AstraZeneca_NN
Annual_JJ
Report_NN
and_CC
Additional_JJ
Information_NOMZ
128_CD
Form_NN
20-F_JJ
Information_NOMZ
2004_CD
for_PIN
US_FPP1
Investors_NN
Additional_JJ
Information_NOMZ
for_PIN
US_FPP1
Investors_NN
continued_VBD
Differences_NN
between_PIN
UK_NN
and_PHC
US_FPP1
accounting_GER
principles_NN
continued_VBD
Net_JJ
income_NN
As_CONJ
a_NULL
result_NULL
of_PIN
the_DT
significant_JJ
difference_NN
between_PIN
the_DT
UK_NN
GAAP_NN
and_PHC
US_FPP1
GAAP_NN
treatment_NOMZ
of_PIN
the_DT
combination_NOMZ
of_PIN
Astra_NN
and_PHC
Zeneca_NN
in_PIN
the_DT
year_NN
of_PIN
acquisition_NOMZ
,_,
and_ANDC
in_PIN
the_DT
results_NN
of_PIN
preceding_VBG
periods_NN
,_,
condensed_JJ
statements_NOMZ
of_PIN
operations_NOMZ
and_PHC
cash_NN
flow_NN
under_IN
US_FPP1
GAAP_NN
have_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
for_PIN
the_DT
benefit_NN
of_PIN
US_FPP1
investors_NN
._.
The_DT
following_GER
is_VPRT [BEMA]
a_DT
summary_NN
of_PIN
the_DT
adjustments_NOMZ
to_PIN
net_JJ
income_NN
and_PHC
shareholders_NN
equity_NOMZ
which_WDT [WHSUB]
would_PRMD
have_VB [PEAS]
been_VBN [PASS]
required_VBN [SUAV]
if_COND
US_FPP1
GAAP_NN
had_VBD [PEAS]
been_VBN [PASS]
applied_VBN
instead_CONJ
of_NULL
UK_NN
GAAP_NN
._.
2004 2003 2002_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD [BEMA]
Net_JJ
income_NN
,_,
as_IN
shown_VBN [PRIV]
in_PIN
the_DT
consolidated_JJ
statements_NOMZ
of_PIN
income_NN
before_IN
exceptional_JJ
items_NN
3,527_CD
3,036_CD
3,186_CD
Exceptional_JJ
items_NN
after_IN
tax_NN
286_CD
350_CD
Net_JJ
income_NN
for_PIN
the_DT
period_NN
under_IN
UK_NN
GAAP_NN
3,813_CD
3,036_CD
2,836_CD
Adjustments_NOMZ
to_TO
conform_VB
to_PIN
US_FPP1
GAAP_NN
Purchase_NN
accounting_GER
adjustments_NOMZ
including_VBG [WZPRES]
goodwill_NN
and_CC
intangibles_VPRT
Deemed_JJ
acquisition_NOMZ
of_PIN
Astra_NN
Amortisation_NOMZ
and_CC
other_JJ
acquisition_NOMZ
adjustments_NOMZ
1,014_CD
952_CD
864_CD
Others_NN
49_CD
59_CD
55_CD
Capitalisation_NOMZ
,_,
less_JJ
disposals_NN
and_PHC
amortisation_NOMZ
of_PIN
interest_NN
1_CD
17_CD
46_CD
Deferred_JJ
taxation_NOMZ
On_PIN
fair_JJ
values_NN
of_PIN
Astra_NN
283 266 239_CD
Others_NN
90_CD
91_CD
99_CD
Pension_NN
and_CC
other_JJ
post-retirement_JJ
benefits_NN
expense_NN
52_CD
43_CD
46_CD
Software_NN
costs_NN
6_CD
18_CD
46_CD
Stock-based_JJ
compensation_NOMZ
11_CD
12_CD
33_CD
Fair_NN
value_NN
of_PIN
financial_JJ
instruments_NOMZ
94_CD
10_CD
93_CD
Research_NN
and_PHC
development_NOMZ
31_CD
Deferred_JJ
income_NN
recognition_NOMZ
14_CD
61_CD
Unrealised_JJ
losses_NN
on_PIN
foreign_JJ
exchange_NN
and_PHC
others_NN
9_CD
18_CD
1_CD
Net_JJ
income_NN
in_PIN
accordance_NN
with_PIN
US_FPP1
GAAP_NN
3,051_CD
2,268_CD
2,307_CD
AstraZeneca_NN
Annual_JJ
Report_NN
and_CC
Additional_JJ
Information_NOMZ
Form_NN
20-F_JJ
Information_NOMZ
2004_CD
for_PIN
US_FPP1
Investors_NN
129_CD
Differences_NN
between_PIN
UK_NN
and_PHC
US_FPP1
accounting_GER
principles_NN
continued_VBD
US_FPP1
GAAP_NN
Condensed_NN
Consolidated_NN
Statement_NOMZ
of_PIN
Operations_NOMZ
2004 2003 2002_CD
For_PIN
the_DT
years_NN
ended_VBN
31_CD
December_NN
$_$
m_CD
$_$
m_CD
$_$
m_CD
Sales_NN
21,426_CD
18,849_CD
17,841_CD
Cost_NN
of_PIN
sales_NN
5,150_CD
4,469_CD
4,520_CD
Distribution_NOMZ
costs_NN
177 162 141_CD
Research_NN
and_PHC
development_NOMZ
3,858_CD
3,451_CD
3,069_CD
Selling_GER
,_,
general_JJ
and_PHC
administrative_JJ
expenses_NN
7,889_CD
6,941_CD
6,165_CD
Amortisation_NOMZ
of_PIN
intangibles_NN
953_CD
881_CD
1,052_CD
Other_JJ
income_NN
534 225 308_CD
Operating_GER
income_NN
3,933_CD
3,170_CD
3,202_CD
Net_JJ
interest_NN
expense_NN
income_NN
1_CD
63_CD
140_CD
Income_NN
from_PIN
continuing_VBG
operations_NOMZ
before_IN
taxation_NOMZ
3,932_CD
3,233_CD
3,342_CD
Taxes_NN
on_PIN
income_NN
from_PIN
continuing_VBG
operations_NOMZ
881_CD
965_CD
1,035_CD
Net_JJ
income_NN
from_PIN
continuing_VBG
operations_NOMZ
3,051_CD
2,268_CD
2,307_CD
Net_JJ
income_NN
for_PIN
the_DT
year_NN
3,051_CD
2,268_CD
2,307_CD
Weighted_VBN
average_JJ
number_NN
of_PIN
$_$
0.25_CD
Ordinary_NN
Shares_NN
in_PIN
issue_NN
millions_NN
1,673_CD
1,709_CD
1,733_CD
Dilutive_JJ
impact_NN
of_PIN
share_NN
options_NOMZ
outstanding_JJ
millions_NN
2_CD
32_CD
Diluted_VBN
weighted_JJ
average_JJ
number_NN
of_PIN
$_$
0.25_CD
Ordinary_NN
Shares_NN
in_PIN
accordance_NN
with_PIN
US_FPP1
GAAP_NN
millions_NN
1,675_CD
1,712_CD
1,735_CD
Net_JJ
income_NN
per_PIN
$_$
0.25_CD
Ordinary_NN
Share_NN
and_PHC
ADS_NN
in_PIN
accordance_NN
with_PIN
US_FPP1
GAAP_NN
basic_JJ
and_PHC
diluted_JJ
$_$
1.82_CD
$_$
1.33_CD
$_$
1.33_CD
US_FPP1
GAAP_NN
Statement_NOMZ
of_PIN
Comprehensive_NN
Income_NN
2004 2003 2002_CD
For_PIN
the_DT
years_NN
ended_VBN
31_CD
December_NN
$_$
m_CD
$_$
m_CD
$_$
m_CD [BEMA]
Net_JJ
income_NN
for_PIN
the_DT
year_NN
3,051_CD
2,268_CD
2,307_CD
Exchange_NN
gains_NN
,_,
net_NN
of_PIN
tax_NN
2,106_CD
3,635_CD
2,919_CD
Other_JJ
movements_NOMZ
,_,
net_NN
of_PIN
tax_NN
20_CD
81_CD
73_CD
Total_JJ
comprehensive_JJ
income_NN
5,177_CD
5,822_CD
5,153_CD
Other_JJ
movements_NOMZ
in_PIN
2004_CD
include_VPRT
a_DT
reduction_NOMZ
in_PIN
the_DT
minimum_JJ
liability_NOMZ
under_IN
SFAS_NN
No._NN
._.
87_CD
Employers_NN
Accounting_GER
for_PIN
Pensions_NN
from_PIN
$_$
39m_CD
to_TO
$_$
36m_CD
._.
Tax_NN
effects_NN
on_PIN
exchange_NN
gains_NN
losses_NN
were_VBD
$_$
82_CD
m_NN
and_CC
on_PIN
other_JJ
movements_NOMZ
$_$
27m_CD
._.
The_DT
cumulative_JJ
exchange_NN
gains_NN
and_PHC
losses_NN
net_NN
of_PIN
tax_NN
on_PIN
the_DT
translation_NOMZ
of_PIN
foreign_JJ
currency_NN
financial_JJ
statements_NOMZ
under_IN
US_FPP1
GAAP_NN
are_VPRT [PASS]
set_VBN
out_PIN
in_PIN
the_DT
following_JJ
note_NN
:_:
2004 2003 2002_CD
For_PIN
the_DT
years_NN
ended_VBN
31_CD
December_NN
$_$
m_CD
$_$
m_CD
$_$
m_CD
Balance_NN
at_PIN
1_CD
January_NN
2,236_CD
1,399_CD
4,318_CD
Movement_NOMZ
in_PIN
year_NN
2,106_CD
3,635_CD
2,919_CD
Balance_NN
at_PIN
31_CD
December_NN
4,342_CD
2,236_CD
1,399_CD
The_DT
cumulative_JJ
total_NN
of_PIN
other_JJ
movements_NOMZ
net_NN
of_PIN
tax_NN
at_PIN
31_CD
December_NN
2004_CD
was_VBD [BEMA]
a_DT
charge_NN
of_PIN
$_$
134m_CD
2003_CD
$_$
154m_CD
,_,
2002_CD
$_$
73m_CD
._.
AstraZeneca_NN
Annual_JJ
Report_NN
and_CC
Additional_JJ
Information_NOMZ
130_CD
Form_NN
20-F_JJ
Information_NOMZ
2004_CD
for_PIN
US_FPP1
Investors_NN
Additional_JJ
Information_NOMZ
for_PIN
US_FPP1
Investors_NN
continued_VBD
Differences_NN
between_PIN
UK_NN
and_PHC
US_FPP1
accounting_GER
principles_NN
continued_VBD
Stock-based_JJ
compensation_NOMZ
In_PIN
the_DT
Groups_NN
Financial_NN
Statements_NOMZ
prepared_VBD
under_IN
UK_NN
GAAP_NN
,_,
no_SYNE
cost_NN
is_VPRT [PASS]
accrued_VBN
for_PIN
the_DT
share_NN
options_NOMZ
awarded_VBN [WZPAST]
to_PIN
employees_NN
under_IN
the_DT
AstraZeneca_NN
Share_NN
Option_NOMZ
Plan_NN
,_,
and_ANDC
the_DT
AstraZeneca_NN
Savings-Related_NN
Share_NN
Option_NOMZ
Plan_NN
as_IN
the_DT
exercise_NN
price_NN
is_VPRT [BEMA]
equivalent_PRED
to_PIN
the_DT
market_NN
value_NN
at_PIN
the_DT
date_NN
of_PIN
grant_NN
._.
Under_IN
US_FPP1
GAAP_NN
the_DT
cost_NN
is_VPRT [PASS]
calculated_VBN [PRIV]
as_IN
the_DT
difference_NN
between_PIN
the_DT
option_NOMZ
price_NN
and_CC
the_DT
market_NN
price_NN
at_PIN
the_DT
date_NN
of_PIN
grant_NN
or_CC
,_,
for_PIN
variable_JJ
plans_NN
,_,
at_PIN
the_DT
end_NN
of_PIN
the_DT
reporting_GER
period_NN
until_IN
measurement_NOMZ
date_NN
._.
Under_IN
the_DT
requirements_NOMZ
of_PIN
APB_NN
Opinion_NN
No._NN
._.
25_CD
any_QUAN
compensation_NOMZ
cost_NN
would_PRMD
be_VB [PASS]
amortised_VBN
over_IN
the_DT
period_NN
from_PIN
the_DT
date_NN
the_DT
options_NOMZ
are_VPRT [PASS]
granted_VBN [SUAV]
to_PIN
the_DT
date_NN
they_TPP3
are_VPRT [BEMA]
first_JJ
exercisable_JJ
._.
Under_IN
US_FPP1
GAAP_NN
in_PIN
the_DT
net_JJ
income_NN
reconciliation_NOMZ
,_,
the_DT
Group_NN
has_VPRT [PEAS]
adjusted_VBN
for_PIN
stock_NN
compensation_NOMZ
costs_NN
as_IN
calculated_VBN [PRIV]
under_IN
APB_NN
Opinion_NN
No._NN
._.
123_CD
Accounting_GER
for_PIN
Stock-Based_NN
Compensation_NOMZ
sets_VPRT
out_PIN
an_DT
alternative_JJ
methodology_NN
for_PIN
recognizing_VBG [PRIV]
the_DT
compensation_NOMZ
cost_NN
based_VBN [WZPAST]
on_PIN
the_DT
fair_JJ
value_NN
at_PIN
grant_NN
date_NN
._.
Had_VBD
the_DT
Group_NN
adopted_VBD
this_DEMO
methodology_NN
,_,
the_DT
incremental_JJ
effect_NN
on_PIN
net_JJ
income_NN
under_IN
US_FPP1
GAAP_NN
is_VPRT [PASS]
shown_VBN [PRIV]
below_PLACE
:_:
2004 2003 2002_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD [BEMA]
Net_JJ
income_NN
under_IN
US_FPP1
GAAP_NN
as_IN
reported_VBN [PUBV]
3,051_CD
2,268_CD
2,307_CD
Compensation_NOMZ
cost_NN
under_IN
APB_NN
No._NN
._.
25_CD
11_CD
12_CD
33_CD
Compensation_NOMZ
cost_NN
under_IN
SFAS_NN
No._NN
._.
123 147 154 122_CD
Pro_PIN
forma_FW
net_JJ
income_NN
2,893_CD
2,126_CD
2,152_CD
Pro_PIN
forma_FW
net_JJ
income_NN
per_PIN
$_$
0.25_CD
Ordinary_NN
Share_NN
and_PHC
ADS_NN
in_PIN
accordance_NN
with_PIN
US_FPP1
GAAP_NN
basic_JJ
and_CC
diluted_VBN
:_:
As_IN
reported_VBN [PUBV]
$_$
1.82_CD
$_$
1.33_CD
$_$
1.33_CD
Pro_PIN
forma_FW
$_$
1.73_CD
$_$
1.24_CD
$_$
1.24_CD
The_DT
fair_JJ
value_NN
of_PIN
options_NOMZ
granted_VBN [SUAV] [WZPAST]
is_VPRT [PASS]
estimated_VBN [PRIV]
,_,
based_VBN [PASTP]
on_PIN
the_DT
stock_NN
price_NN
at_PIN
the_DT
grant_NN
date_NN
,_,
using_VBG [PRESP]
the_DT
Black-Scholes_NN
option_NOMZ
pricing_GER
model_NN
with_PIN
the_DT
following_VBG
assumptions_NOMZ
:_:
2004 2003 2002_CD
Dividend_NN
yield_NN
2.3_CD
%_NN
2.0_CD
%_NN
1.6_CD
%_NN
Expected_VBN [PRIV]
volatility_NOMZ
25.0_CD
%_NN
25.0_CD
%_NN
30.0_CD
%_NN
Risk-free_JJ
interest_NN
rate_NN
3.5_CD
%_NN
4.3_CD
%_NN
5.2_CD
%_NN
Expected_VBN [PRIV]
lives_NN
:_:
AstraZeneca_NN
Share_NN
Option_NOMZ
Plan_NN
6.0_CD
years_NN
6.0_CD
years_NN
6.0_CD
years_NN
Expected_VBN [PRIV]
lives_NN
:_:
SAYE_NN
Plan_NN
3.8_CD
years_NN
4.3_CD
years_NN
4.3_CD
years_NN
AstraZeneca_NN
Annual_JJ
Report_NN
and_CC
Additional_JJ
Information_NOMZ
Form_NN
20-F_JJ
Information_NOMZ
2004_CD
for_PIN
US_FPP1
Investors_NN
131_CD
Differences_NN
between_PIN
UK_NN
and_PHC
US_FPP1
accounting_GER
principles_NN
continued_VBD
Pension_NN
and_PHC
post-retirement_NOMZ
benefits_NN
For_PIN
the_DT
purposes_NN
of_PIN
US_FPP1
GAAP_NN
,_,
the_DT
pension_NN
information_NOMZ
as_IN
set_VBN
out_PIN
in_PIN
Note_NN
28_CD
in_PIN
respect_NN
of_PIN
the_DT
UK_NN
retirement_NOMZ
plans_NN
and_CC
of_PIN
the_DT
retirement_NOMZ
plans_NN
of_PIN
the_DT
non-UK_JJ
subsidiaries_NN
has_VPRT [PEAS]
been_VBN [PASS]
restated_VBN
in_PIN
the_DT
following_VBG
tables_NN
in_PIN
accordance_NN
with_PIN
the_DT
requirements_NOMZ
of_PIN
SFAS_NN
No._NN
._.
132_CD
Employers_NN
Disclosures_NN
about_IN
Pensions_NN
and_CC
Other_JJ
Postretirement_NOMZ
Benefits_NN
,_,
an_DT
amendment_NOMZ
of_PIN
FASB_NN
Statements_NOMZ
No._NN
._.
These_DEMO
plans_NN
comprise_VPRT
substantially_RB
all_QUAN
of_PIN
the_DT
actuarial_JJ
liabilities_NOMZ
of_PIN
all_QUAN
AstraZeneca_NN
retirement_NOMZ
plans_NN
._.
The_DT
changes_NN
in_PIN
projected_VBN
benefit_NN
obligations_NOMZ
,_,
plan_NN
assets_NN
and_PHC
details_NN
of_PIN
the_DT
funded_JJ
status_NN
of_PIN
these_DEMO
retirement_NOMZ
plans_NN
,_,
together_RB
with_PIN
the_DT
changes_NN
in_PIN
the_DT
accumulated_VBN
other_JJ
post-retirement_JJ
benefit_NN
obligations_NOMZ
,_,
under_IN
SFAS_NN
No._NN
._.
132_CD
are_VPRT
as_IN
follows_VPRT
:_:
Other_JJ
Pension_NN
post-retirement_NOMZ
benefits_NN
benefits_NN
Change_NN
in_PIN
projected_VBN
benefit_NN
obligation_NOMZ
2004 2003 2004 2003_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Benefit_NN
obligation_NOMZ
at_PIN
beginning_GER
of_PIN
year_NN
7,416_CD
5,943_CD
242_CD
210_CD
Service_NN
cost_NN
229_CD
171_CD
11_CD
9_CD
Interest_NN
cost_NN
385_CD
329_CD
14_CD
14_CD
Participant_NN
contributions_NOMZ
30_CD
26_CD
1_CD
1_CD
Actuarial_JJ
loss_NN
gain_NN
328_CD
545_CD
3_CD
24_CD
Special_JJ
termination_NOMZ
benefits_NN
Settlement_NOMZ
and_PHC
curtailment_NOMZ
10_CD
5_CD
Benefits_NN
paid_VBN
281_CD
245_CD
18_CD
19_CD
Exchange_NN
590_CD
642_CD
2_CD
3_CD
Benefit_NN
obligation_NOMZ
at_PIN
end_NN
of_PIN
year_NN
8,707_CD
7,416_CD
249_CD
242_CD
Other_JJ
Pension_NN
post-retirement_NOMZ
benefits_NN
benefits_NN
Change_NN
in_PIN
plan_NN
assets_NN
2004 2003 2004 2003_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Fair_NN
value_NN
at_PIN
beginning_GER
of_PIN
year_NN
5,905_CD
4,549_CD
195_CD
133_CD
Actual_JJ
return_NN
on_PIN
plan_NN
assets_NN
565_CD
590_CD
22_CD
35_CD
Group_NN
contribution_NOMZ
280_CD
489_CD
17_CD
43_CD
Participant_NN
contributions_NOMZ
30_CD
26_CD
1_CD
Settlement_NOMZ
and_PHC
curtailment_NOMZ
Benefits_NN
paid_VBD
281_CD
245_CD
17_CD
17_CD
Exchange_NN
473_CD
496_CD
Fair_NN
value_NN
of_PIN
plan_NN
assets_NN
at_PIN
end_NN
of_PIN
year_NN
6,972_CD
5,905_CD
217_CD
195_CD
Funded_VBN
status_NN
of_PIN
plans_NN
1,735_CD
1,511_CD
32_CD
47_CD
Unrecognised_JJ
net_JJ
loss_NN
1,644_CD
1,503_CD
29_CD
36_CD
Prior_RB
service_NN
cost_NN
not_XX0
recognized_VBN [PRIV]
15_CD
25_CD
11_CD
9_CD
Unrecognised_JJ
net_JJ
obligation_NOMZ
on_PIN
implementation_NOMZ
1_CD
1_CD
25_CD
29_CD
77_CD
16_CD
11_CD
9_CD
Adjustments_NOMZ
to_TO
recognize_VB [PRIV]
minimum_JJ
liability_NOMZ
:_:
Intangible_JJ
assets_NN
36_CD
39_CD
Accumulated_VBN
other_JJ
comprehensive_JJ
income_NN
217_CD
260_CD
Accrued_VBN
benefit_NN
asset_NN
liability_NOMZ
330_CD
283_CD
11_CD
9_CD
At_PIN
31_CD
December_NN
2004_CD
,_,
the_DT
projected_VBN
benefit_NN
obligation_NOMZ
,_,
accumulated_VBN
benefit_NN
obligation_NOMZ
and_CC
fair_JJ
value_NN
of_PIN
the_DT
plan_NN
assets_NN
in_PIN
respect_NN
of_PIN
the_DT
pension_NN
plans_NN
above_PLACE
with_PIN
accumulated_VBN
benefit_NN
obligations_NOMZ
in_PIN
excess_NN
of_PIN
plan_NN
assets_NN
were_VBD
$_$
6,699_CD
m_NN
,_,
$_$
5,800_CD
m_NN
and_CC
$_$
5,220_CD
m_NN
,_,
2003_CD
$_$
5,779_CD
m_NN
,_,
$_$
4,961_CD
m_NN
and_CC
$_$
4,415_CD
m_NN
respectively_RB
._.
The_DT
total_NN
of_PIN
accumulated_VBN
benefit_NN
obligations_NOMZ
for_PIN
the_DT
pension_NN
plans_NN
was_VBD
$_$
7,443_CD
m_NN [BEMA]
2003_CD
$_$
6,239_CD
m._FW
The_DT
measurement_NOMZ
date_NN
for_PIN
the_DT
plan_NN
assets_NN
and_PHC
benefit_NN
obligations_NOMZ
set_VBN [WZPAST]
out_PIN
above_PLACE
was_VBD [BEMA]
31_CD
December_NN
2004_CD
._.
Contributions_NOMZ
to_PIN
the_DT
plans_NN
in_PIN
2005_CD
are_VPRT [PASS]
estimated_VBN [PRIV]
to_TO
be_VB
$_$
224m_CD
._.
AstraZeneca_NN
Annual_JJ
Report_NN
and_CC
Additional_JJ
Information_NOMZ
132_CD
Form_NN
20-F_JJ
Information_NOMZ
2004_CD
for_PIN
US_FPP1
Investors_NN
Additional_JJ
Information_NOMZ
for_PIN
US_FPP1
Investors_NN
continued_VBD
Differences_NN
between_PIN
UK_NN
and_PHC
US_FPP1
accounting_GER
principles_NN
continued_VBD
Assumed_JJ
discount_NN
rates_NN
and_PHC
rates_NN
of_PIN
increase_NN
in_PIN
remuneration_NOMZ
used_VBN [WZPAST]
in_PIN
calculating_VBG [PRIV]
the_DT
projected_VBN
benefit_NN
obligations_NOMZ
together_RB
with_PIN
long_JJ
term_NN
rates_NN
of_PIN
return_NN
on_PIN
plan_NN
assets_NN
vary_VPRT
according_VBG
to_PIN
the_DT
economic_JJ
conditions_NOMZ
of_PIN
the_DT
country_NN
in_PIN
which_WDT [PIRE]
the_DT
retirement_NOMZ
plans_NN
are_VPRT [PASS]
situated_VBN
._.
The_DT
weighted_JJ
average_NN
rates_NN
used_VBN [WZPAST]
for_PIN
calculation_NOMZ
of_PIN
year_NN
end_NN
benefit_NN
obligations_NOMZ
and_PHC
forecast_NN
benefit_NN
cost_NN
in_PIN
the_DT
retirement_NOMZ
plans_NN
and_CC
other_JJ
benefit_NN
obligations_NOMZ
for_PIN
SFAS_NN
No._NN
._.
132_CD
purposes_NN
were_VBD
as_IN
follows_VPRT
:_:
Pension_NN
benefits_NN
Other_JJ
post-retirement_NOMZ
benefits_NN
2004 2003 2002 2004_CD
2003_CD
2002_CD
%_NN
%_NN
%_NN
%_NN
%_NN
%_NN
Discount_NN
rate_NN
5.2_CD
5.5_CD
5.8_CD
5.7_CD
5.9_CD
6.6_CD
Long_JJ
term_NN
rate_NN
of_PIN
increase_NN
in_PIN
remuneration_NOMZ
3.9_CD
4.0_CD
4.1_CD
n_VBD
a_DT
n_NN
a_DT
n_NN
a_DT
Expected_VBN [PRIV]
long_JJ
term_NN
return_NN
on_PIN
assets_NN
6.8_CD
6.6_CD
6.4_CD
7.8_CD
7.8_CD
7.8_CD
The_DT
Group_NN
has_VPRT [PEAS]
assumed_VBN [PRIV]
a_DT
long_JJ
term_NN
rate_NN
of_PIN
increase_NN
in_PIN
healthcare_NN
costs_NN
of_PIN
8_CD
%_NN
,_,
reducing_VBG [PRESP]
to_PIN
4_CD
%_NN
._.
Pension_NN
benefits_NN
Other_JJ
post-retirement_NOMZ
benefits_NN
2004 2003 2002 2004_CD
2003_CD
2002_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD [BEMA]
Net_JJ
periodic_JJ
cost_NN
Service_NN
cost_NN
present_JJ
value_NN
of_PIN
benefits_NN
accruing_VBG [WZPRES]
during_PIN
the_DT
year_NN
229 171 146_CD
11_CD
98_CD
Interest_NN
cost_NN
on_PIN
projected_VBN
benefit_NN
obligations_NOMZ
385 329 287_CD
14_CD
14_CD
14_CD
Expected_VBN [PRIV]
return_NN
on_PIN
assets_NN
406 308 276_CD
15_CD
14_CD
Net_JJ
amortisation_NOMZ
and_CC
deferral_JJ
76_CD
45_CD
34_CD
3_CD
2_CD
1_CD
Net_JJ
periodic_JJ
cost_NN
for_PIN
the_DT
year_NN
284 237 191_CD
13_CD
11_CD
21_CD
It_PIT
is_VPRT [PASS]
estimated_VBN [PRIV]
that_THVC
a_DT
one_CD
percentage_NN
point_NN
change_NN
in_PIN
the_DT
weighted_JJ
average_JJ
healthcare_NN
costs_NN
trend_NN
would_PRMD
have_VB
the_DT
following_JJ
effects_NN
on_PIN
the_DT
accumulated_VBN
benefit_NN
obligation_NOMZ
and_CC
net_JJ
periodic_JJ
cost_NN
at_PIN
31_CD
December_NN
2004_CD
:_:
One_CD
percentage_NN
point_NN
Increase_VPRT
Decrease_NN
$_$
m_CD
$_$
m_CD [PASS]
Accumulated_VBN
benefit_NN
obligation_NOMZ
15_CD
13_CD
Net_JJ
periodic_JJ
cost_NN
2_CD
2_CD
The_DT
weighted_JJ
average_JJ
allocation_NOMZ
of_PIN
pension_NN
and_CC
other_JJ
post-retirement_JJ
plan_NN
assets_NN
was_VBD
as_IN
follows_VPRT
:_:
2004_CD
2003_CD
%_NN
%_NN
Equities_NOMZ
49.7_CD
49.2_CD
Bonds_NN
36.0_CD
48.8_CD
Other_JJ
14.3_CD
2.0_CD
The_DT
benefits_NN
expected_VBN [PRIV]
to_TO
be_VB [PASS]
paid_VBN
in_PIN
the_DT
future_NN
are_VPRT
as_IN
follows_VPRT
:_:
$_$
m_CD [BEMA]
2005 326 2006 337_CD
2007 349 2008 362_CD
2009 376 2010 2014_CD
1,761_CD
AstraZeneca_NN
Annual_JJ
Report_NN
and_CC
Additional_JJ
Information_NOMZ
Form_NN
20-F_JJ
Information_NOMZ
2004_CD
for_PIN
US_FPP1
Investors_NN
133_CD
Differences_NN
between_PIN
UK_NN
and_PHC
US_FPP1
accounting_GER
principles_NN
continued_VBD
Taxation_NOMZ
2004 2003 2002_CD
Years_NN
ended_VBD
31_CD
December_NN
$_$
m_CD
$_$
m_CD
$_$
m_CD
Taxes_NN
on_PIN
income_NN
from_PIN
continuing_VBG
operations_NOMZ
UK_NN
taxation_NOMZ
Corporation_NOMZ
tax_NN
379 138 165_CD
Double_RB
taxation_NOMZ
relief_NN
22_CD
23_CD
7_CD
Adjustment_NOMZ
in_PIN
respect_NN
of_PIN
prior_JJ
period_NN
178_CD
Deferred_JJ
taxation_NOMZ
47_CD
88_CD
40_CD
Overseas_PLACE
taxation_NOMZ
Overseas_PLACE
taxes_NN
992 878 921_CD
Adjustments_NOMZ
in_PIN
respect_NN
of_PIN
prior_JJ
periods_NN
7_CD
35_CD
51_CD
Deferred_JJ
taxation_NOMZ
250_CD
151_CD
33_CD
Share_NN
of_PIN
taxation_NOMZ
of_PIN
joint_JJ
ventures_NN
and_PHC
associates_NN
Taxes_NN
on_PIN
income_NN
from_PIN
continuing_VBG
operations_NOMZ
881_CD
965_CD
1,035_CD
The_DT
table_NN
below_PLACE
reconciles_NN
the_DT
UK_NN
statutory_JJ
tax_NN
charge_NN
with_PIN
the_DT
Groups_NN
actual_JJ
charge_NN
on_PIN
income_NN
from_PIN
continuing_VBG
operations_NOMZ
._.
2004 2003 2002_CD
Years_NN
ended_VBD
31_CD
December_NN
$_$
m_CD
$_$
m_CD
$_$
m_CD
Income_NN
on_PIN
continuing_VBG
operations_NOMZ
3,932_CD
3,233_CD
3,342_CD
Taxation_NOMZ
charge_NN
at_PIN
UK_NN
corporation_NOMZ
tax_NN
rate_NN
of_PIN
30_CD
%_NN
for_PIN
2004_CD
30_CD
%_NN
for_PIN
2003_CD
,_,
30_CD
%_NN
for_PIN
2002_CD
1,180_CD
970_CD
1,002_CD
Differences_NN
in_PIN
effective_JJ
overseas_PLACE
tax_NN
rates_NN
27_CD
41_CD
6_CD
Items_NN
not_XX0
deductible_JJ
for_PIN
tax_NN
purposes_NN
40_CD
89_CD
83_CD
Items_NN
not_XX0
chargeable_JJ
for_PIN
tax_NN
purposes_NN
71_CD
88_CD
110_CD
Adjustments_NOMZ
in_PIN
respect_NN
of_PIN
prior_JJ
periods_NN
171_CD
35_CD
51_CD
Exceptional_JJ
items_NN
124_CD
105_CD
Tax_NN
on_PIN
income_NN
from_PIN
continuing_VBG
operations_NOMZ
881_CD
965_CD
1,035_CD
In_PIN
2004_CD
,_,
claims_VPRT [PUBV]
amounting_VBG
to_TO
$_$
nil_JJ
2003_CD
$_$
95m_CD
for_PIN
tax_NN
relief_NN
were_VBD [PASS]
made_VBN
arising_VBG
as_CONJ
a_NULL
result_NULL
of_PIN
a_DT
restructuring_GER
of_PIN
the_DT
AMI_NN
joint_JJ
venture_NN
in_PIN
1998_CD
._.
Under_IN
US_FPP1
GAAP_NN
,_,
these_DEMO
reliefs_NN
are_VPRT [PASS]
adjusted_VBN
against_PIN
the_DT
goodwill_NN
arising_VBG [WZPRES]
on_PIN
the_DT
restructuring_GER
and_CC
included_VBD
in_PIN
other_JJ
adjustments_NOMZ
._.
AstraZeneca_NN
Annual_JJ
Report_NN
and_CC
Additional_JJ
Information_NOMZ
134_CD
Form_NN
20-F_JJ
Information_NOMZ
2004_CD
for_PIN
US_FPP1
Investors_NN
Additional_JJ
Information_NOMZ
for_PIN
US_FPP1
Investors_NN
continued_VBD
Differences_NN
between_PIN
UK_NN
and_PHC
US_FPP1
accounting_GER
principles_NN
continued_VBD
Shareholders_NN
equity_NOMZ
2004_CD
2003_CD
$_$
m_CD
$_$
m_CD [BEMA]
Total_JJ
shareholders_NN
equity_NOMZ
under_IN
UK_NN
GAAP_NN
14,418_CD
13,178_CD
Adjustments_NOMZ
to_TO
conform_VB
to_PIN
US_FPP1
GAAP_NN
Purchase_NN
accounting_GER
adjustments_NOMZ
including_VBG [WZPRES]
goodwill_NN
and_CC
intangibles_VPRT
Deemed_JJ
acquisition_NOMZ
of_PIN
Astra_NN
Goodwill_NN
15,099_CD
14,311_CD
Tangible_JJ
and_PHC
intangible_JJ
fixed_VBN
assets_NN
6,988_CD
7,661_CD
Others_NN
206_CD
145_CD
Capitalisation_NOMZ
,_,
less_JJ
disposals_NN
and_PHC
amortisation_NOMZ
of_PIN
interest_NN
254_CD
255_CD
Deferred_JJ
taxation_NOMZ
On_PIN
fair_JJ
value_NN
of_PIN
Astra_NN
2,134_CD
2,313_CD
Others_NN
92_CD
207_CD
Dividend_NN
1,061_CD
914_CD
Pension_NN
and_CC
other_JJ
post-retirement_JJ
benefits_NN
expense_NN
573_CD
534_CD
Software_NN
costs_NN
capitalized_JJ
52_CD
46_CD
Fair_NN
value_NN
of_PIN
financial_JJ
instruments_NOMZ
2_CD
109_CD
Deferred_JJ
income_NN
recognition_NOMZ
Others_NN
33_CD
89_CD
Shareholders_NN
equity_NOMZ
in_PIN
accordance_NN
with_PIN
US_FPP1
GAAP_NN
35,314_CD
33,654_CD
Acquired_VBN
intangible_JJ
assets_NN
Details_NN
of_PIN
the_DT
carrying_VBG
amounts_NN
of_PIN
intangible_JJ
fixed_JJ
assets_NN
and_CC
past_JJ
and_CC
projected_VBD
amortisation_NOMZ
expenses_NN
are_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
._.
2004_CD
2003_CD
Gross_NN
Gross_NN
carrying_VBG [WZPRES]
Accumulated_NN
carrying_VBG [WZPRES]
Accumulated_NN
amount_NN
amortisation_NOMZ
amount_NN
amortisation_NOMZ
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Product_NN
rights_NN
14,590_CD
6,744_CD
13,733_CD
5,274_CD
Marketing_GER
and_PHC
distribution_NOMZ
rights_NN
1,729_CD
1,043_CD
1,659_CD
831_CD
Software_NN
589 367 462 305_CD
Others_NN
460 360 421 329_CD
Total_JJ
17,368_CD
8,514_CD
16,275_CD
6,739_CD
Aggregate_NN
amortisation_NOMZ
expense_NN
$_$
m_CD [BEMA]
For_PIN
year_NN
ended_VBD
31_CD
December_NN
2004_CD
1,316_CD
For_PIN
year_NN
ended_VBD
31_CD
December_NN
2003_CD
1,245_CD
For_PIN
year_NN
ended_VBD
31_CD
December_NN
2002_CD
1,154_CD
Estimated_VBN [PRIV]
amortisation_NOMZ
expense_NN
$_$
m_CD [BEMA]
For_PIN
year_NN
ended_VBD
31_CD
December_NN
2005_CD
1,316_CD
For_PIN
year_NN
ended_VBD
31_CD
December_NN
2006_CD
1,304_CD
For_PIN
year_NN
ended_VBD
31_CD
December_NN
2007_CD
1,216_CD
For_PIN
year_NN
ended_VBD
31_CD
December_NN
2008_CD
1,216_CD
For_PIN
year_NN
ended_VBD
31_CD
December_NN
2009_CD
1,216_CD
AstraZeneca_NN
Annual_JJ
Report_NN
and_CC
Additional_JJ
Information_NOMZ
Form_NN
20-F_JJ
Information_NOMZ
2004_CD
for_PIN
US_FPP1
Investors_NN
135_CD
Differences_NN
between_PIN
UK_NN
and_PHC
US_FPP1
accounting_GER
principles_NN
continued_VBD
The_DT
weighted_JJ
average_JJ
amortisation_NOMZ
period_NN
in_PIN
respect_NN
of_PIN
each_QUAN
class_NN
of_PIN
intangible_JJ
asset_NN
is_VPRT
as_IN
follows_VPRT
:_:
Product_NN
rights_NN
13_CD
years_NN
Marketing_GER
and_PHC
distribution_NOMZ
rights_NN
16_CD
years_NN
Software_NN
4_CD
years_NN
Other_JJ
8_CD
years_NN
Goodwill_NN
The_DT
changes_NN
in_PIN
the_DT
carrying_VBG
amount_NN
of_PIN
goodwill_NN
for_PIN
the_DT
two_CD
years_NN
ended_VBN
31_CD
December_NN
2004_CD
were_VBD
as_IN
follows_VPRT
:_:
$_$
m_CD
Balance_NN
as_IN
at_PIN
1_CD
January_NN
2003_CD
13,647_CD
Acquired_VBN
1_CD
Exchange_NN
adjustments_NOMZ
1,658_CD
Balance_NN
as_IN
at_PIN
1_CD
January_NN
2004_CD
15,306_CD
Exchange_NN
and_CC
other_JJ
movements_NOMZ
837_CD
Balance_NN
as_IN
at_PIN
31_CD
December_NN
2004_CD
16,143_CD
US_FPP1
GAAP_NN
Condensed_NN
Consolidated_NN
Statement_NOMZ
of_PIN
Cash_NN
Flows_NN
2004 2003 2002_CD
For_PIN
the_DT
years_NN
ended_VBN
31_CD
December_NN
$_$
m_CD
$_$
m_CD
$_$
m_CD
Cash_NN
flows_VPRT
from_PIN
operating_VBG
activities_NOMZ
4,842_CD
3,416_CD
4,833_CD
Cash_NN
flows_VPRT
from_PIN
investing_VBG
activities_NOMZ
Movement_NOMZ
in_PIN
short_JJ
term_NN
investments_NOMZ
and_CC
fixed_VBN
deposits_NN
862 771 806_CD
New_NN
fixed_JJ
asset_NN
investments_NOMZ
117_CD
120_CD
1_CD
Disposal_NN
of_PIN
fixed_JJ
assets_NN
35_CD
38_CD
66_CD
Acquisitions_NOMZ
and_PHC
disposals_NN
355_CD
80_CD
Capital_NN
expenditure_NN
1,183_CD
1,515_CD
1,608_CD
Net_JJ
cash_NN
outflows_NN
from_PIN
investing_VBG
activities_NOMZ
1,772_CD
746_CD
2,349_CD
Net_JJ
cash_NN
flow_NN
before_IN
financing_VBG
3,070_CD
2,670_CD
2,484_CD
Cash_NN
flows_VPRT
from_PIN
financing_VBG
activities_NOMZ
Equity_NOMZ
dividends_NN
paid_VBD
1,378_CD
1,222_CD
1,234_CD
Re-purchase_NN
of_PIN
AstraZeneca_NN
PLC_NN
Ordinary_NN
Shares_NN
2,110_CD
1,107_CD
1,154_CD
Net_JJ
increase_NN
decrease_NN
in_PIN
short_JJ
term_NN
borrowings_GER
2_CD
13_CD
New_JJ
loans_NN
loans_NN
repaid_VBN
725 345 105_CD
Net_JJ
cash_NN
outflows_NN
from_PIN
financing_VBG
activities_NOMZ
2,761_CD
2,674_CD
2,506_CD
Increase_VPRT
decrease_NN
in_PIN
cash_NN
309_CD
4_CD
22_CD
Cash_NN
:_:
At_PIN
1_CD
January_NN
581 524 510_CD
Increase_VB
decrease_NN
in_PIN
cash_NN
309_CD
4_CD
22_CD
Exchange_NN
movements_NOMZ
23_CD
61_CD
36_CD
At_PIN
31_CD
December_NN
913 581 524_CD
Interest_NN
paid_VBN [WZPAST]
was_VBD
$_$
62m_CD
in_PIN
2004_CD
2003_CD
$_$
32m_CD
,_,
2002_CD
$_$
96m_CD
._.
